anti fasl  (Santa Cruz Biotechnology)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: COX-2/PGE 2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation

doi: 10.1186/s13046-025-03582-6

Figure Lengend Snippet: Changes in the COX-2/PGE 2 /NK cell axis after iRFA. A Immunohistochemical staining of COX-2 expression in human HCC with or without RFA. B Intratumoral PGE 2 levels in human HCC patients with or without prior RFA therapy. C Immunofluorescence micrographs of NK cell infiltration in human HCC. D Immunohistochemical staining of COX-2 expression in murine orthotopic HCC models with or without iRFA. E Western blot analysis of TRAIL, FASL and COX-2 expression in murine orthotopic HCC tumor tissues from different groups. (F) ELISA analysis of PGE 2 secretion by NK92 cells treated with or without iRFA treatment. G SEM images of NK92 cells treated with different concentrations of PGE 2 . H Flow cytometry analysis and corresponding bar charts of activating and inhibitory receptors on NK92 cells treated with PGE 2 . I ELISA analysis of IFN-γ and TNF-α secretion by NK92 cells treated with PGE 2 . (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; RFA, radiofrequency ablation; iRFA, incomplete radiofrequency ablation; PGE 2 , prostaglandin E2)

Article Snippet: Specific primary antibodies were used to detect TRAIL (GB11413-100, 1:1000 dilution, Servicebio, China), FASL (GB11090-100, 1:1000 dilution, Servicebio, China), and COX-2 (GB115672-100, 1:1000 dilution, Servicebio, China).

Techniques: Immunohistochemical staining, Staining, Expressing, Immunofluorescence, Western Blot, Enzyme-linked Immunosorbent Assay, Flow Cytometry

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: COX-2/PGE 2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation

doi: 10.1186/s13046-025-03582-6

Figure Lengend Snippet: Celecoxib reverses post-iRFA alterations. A ELISA analysis of PGE 2 secretion by NK92 cells after ablation and treated with different concentrations of celecoxib. B Immunohistochemical staining for COX-2 expression in tumors from iRFA-treated mice ± celecoxib. C PGE 2 concentrations in peripheral blood and tumor tissues of iRFA-treated mice ± celecoxib. D qRT-PCR analysis of mRNA expression levels of cytolytic effector molecules (TRAIL, FASL, Perforin, Granzyme B) in tumor tissues. ( n = 5, * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; iRFA, incomplete radiofrequency ablation; αPD-1, anti-PD-1 antibody; CXB, celecoxib)

Article Snippet: Specific primary antibodies were used to detect TRAIL (GB11413-100, 1:1000 dilution, Servicebio, China), FASL (GB11090-100, 1:1000 dilution, Servicebio, China), and COX-2 (GB115672-100, 1:1000 dilution, Servicebio, China).

Techniques: Enzyme-linked Immunosorbent Assay, Immunohistochemical staining, Staining, Expressing, Quantitative RT-PCR